|
May 28
|
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
|
|
May 27
|
AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment
|
|
May 27
|
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 23
|
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially
|
|
May 23
|
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
|
|
May 12
|
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower
|
|
May 12
|
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
|
|
May 12
|
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
|
|
May 12
|
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices
|
|
May 12
|
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
|
|
May 10
|
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
|
|
May 9
|
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
|
|
May 9
|
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
|
|
May 9
|
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
|
|
May 8
|
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
|
|
May 7
|
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
|
|
May 7
|
Q1 2025 Arcus Biosciences Inc Earnings Call
|
|
May 7
|
Expediting parallel drug approval pathways is challenging, but rewarding
|
|
May 7
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
|